FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BCAS3-PRKAA2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BCAS3-PRKAA2
FusionPDB ID: 9226
FusionGDB2.0 ID: 9226
HgeneTgene
Gene symbol

BCAS3

PRKAA2

Gene ID

54828

5563

Gene nameBCAS3 microtubule associated cell migration factorprotein kinase AMP-activated catalytic subunit alpha 2
SynonymsGAOB1|MAABAMPK|AMPK2|AMPKa2|PRKAA
Cytomap

17q23.2

1p32.2

Type of geneprotein-codingprotein-coding
Descriptionbreast carcinoma-amplified sequence 3BCAS4/BCAS3 fusionRudhirabreast carcinoma amplified sequence 4/3 fusion proteinmetastasis associated antigen of breast cancerprotein Maab15'-AMP-activated protein kinase catalytic subunit alpha-25'-AMP-activated protein kinase, catalytic alpha-2 chainACACA kinaseAMP-activated protein kinase alpha-2 subunit variant 2AMP-activated protein kinase alpha-2 subunit variant 3AMPK alpha 2AMPK
Modification date2020031320200327
UniProtAcc

Q9H6U6

Main function of 5'-partner protein: FUNCTION: Plays a role in angiogenesis. Participates in the regulation of cell polarity and directional endothelial cell migration by mediating both the activation and recruitment of CDC42 and the reorganization of the actin cytoskeleton at the cell leading edge. Promotes filipodia formation (By similarity). Functions synergistically with PELP1 as a transcriptional coactivator of estrogen receptor-responsive genes. Stimulates histone acetyltransferase activity. Binds to chromatin. {ECO:0000250|UniProtKB:Q8CCN5, ECO:0000269|PubMed:17505058}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000390652, ENST00000407086, 
ENST00000408905, ENST00000588462, 
ENST00000589222, ENST00000585744, 
ENST00000585812, ENST00000588874, 
ENST00000371244, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score53 X 35 X 17=315352 X 3 X 2=12
# samples 612
** MAII scorelog2(61/31535*10)=-5.69200088030826
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(2/12*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: BCAS3 [Title/Abstract] AND PRKAA2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BCAS3 [Title/Abstract] AND PRKAA2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BCAS3(58885437)-PRKAA2(57157067), # samples:2
Anticipated loss of major functional domain due to fusion event.BCAS3-PRKAA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
BCAS3-PRKAA2 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBCAS3

GO:0043085

positive regulation of catalytic activity

17505058

HgeneBCAS3

GO:0045944

positive regulation of transcription by RNA polymerase II

17505058

HgeneBCAS3

GO:0071391

cellular response to estrogen stimulus

17505058



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:58885437/chr1:57157067)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BCAS3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PRKAA2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000589222BCAS3chr1758885437+ENST00000371244PRKAA2chr157157067+9589544681966632
ENST00000407086BCAS3chr1758885437+ENST00000371244PRKAA2chr157157067+9569524481946632
ENST00000390652BCAS3chr1758885437+ENST00000371244PRKAA2chr157157067+9552507311929632
ENST00000408905BCAS3chr1758885437+ENST00000371244PRKAA2chr157157067+952147601898632
ENST00000588462BCAS3chr1758885437+ENST00000371244PRKAA2chr157157067+952147601898632

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000589222ENST00000371244BCAS3chr1758885437+PRKAA2chr157157067+7.96E-050.99992037
ENST00000407086ENST00000371244BCAS3chr1758885437+PRKAA2chr157157067+7.92E-050.99992085
ENST00000390652ENST00000371244BCAS3chr1758885437+PRKAA2chr157157067+7.86E-050.99992144
ENST00000408905ENST00000371244BCAS3chr1758885437+PRKAA2chr157157067+7.83E-050.9999217
ENST00000588462ENST00000371244BCAS3chr1758885437+PRKAA2chr157157067+7.83E-050.9999217

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BCAS3-PRKAA2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BCAS3chr1758885437PRKAA2chr157157067476159PLLGVCKSIGSSGYQVISTPTDFFMV
BCAS3chr1758885437PRKAA2chr157157067507159PLLGVCKSIGSSGYQVISTPTDFFMV
BCAS3chr1758885437PRKAA2chr157157067524159PLLGVCKSIGSSGYQVISTPTDFFMV
BCAS3chr1758885437PRKAA2chr157157067544159PLLGVCKSIGSSGYQVISTPTDFFMV

Top

Potential FusionNeoAntigen Information of BCAS3-PRKAA2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of BCAS3-PRKAA2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BCAS3-PRKAA2_58885437_57157067.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0401GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0401SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0401IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0403GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0403SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0403IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0405GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0405IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0405SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0405SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0405SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0407GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0407SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0407IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0407SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0409GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0409IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0409SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0409SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0409SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0411GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0411SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0411IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0417GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0417SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0417IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0417SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0417SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0419GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0419SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0419IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0424GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0424SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0424IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0424SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0424SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0427SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0427GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0427IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0429GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0429IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0429SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0429SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0429SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0430GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0430IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0430SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0430SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0430SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0431GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0431SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0431IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0433GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0433SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0433IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0434GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0434SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0435GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0435SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0435IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0438GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0438SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0438IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0439GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0439SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0439IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0441GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0441SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0441IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0443GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0443SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0443IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0445GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0445IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0445SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0445SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0445SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0446GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0446SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0446IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0447GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0447SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0447IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0448GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0448IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0448SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0448SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0448SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0449GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0449SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0449IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0450GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0450SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0450IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0451GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0451SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0451IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0452GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0452SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0452IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0454GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0454SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0454IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0457GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0457IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0457SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0457SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0457SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0459GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0459SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0459IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0460GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0460SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0460IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0461GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0461SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0461IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0462GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0462SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0462IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0462SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0462SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0463GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0463SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0463IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0464GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0464SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0464IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0465GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0465SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0467GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0469GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0469SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0469IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0469SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0469SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0471GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0471SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0471IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0474GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0474SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0474IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0475GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0475SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0475IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0476GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0476SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0476IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0477GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0477IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0477SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0477SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0477SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0478GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0478SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0480GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0480SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0480IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0480SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0480SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0482GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0482SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0482IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0482SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0483GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0483IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0483SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0483SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0483SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0484GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0484IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0484SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0484SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0484SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0485GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0485SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0485IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0486GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0486SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0486IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0486SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0486SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0487GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0487IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0487SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0487SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0487SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0488GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0488SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0488IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0489GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0489IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0489SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0489SIGSSGYQVISTPTD722
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0489SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0491GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0491SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0491IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0801GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0801SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0801IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0803GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0803SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0803IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0805GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0805SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0805IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0807GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0808GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0808SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0811GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0811SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0814GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0814SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0814IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0816GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0816SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0816IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0818GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0818SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0818IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0818SGYQVISTPTDFFMV1126
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0823GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0823SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0823IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0825GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0825SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0826GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0826SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0826IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0827GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0827SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0827IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0829GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0829SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0829IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0832GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0832SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0832IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0833GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0833SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0833IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0835GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0835SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0835IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0836GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0836SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0836IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0837GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0837SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0838GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0838SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0838IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0839GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0839SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0839IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0840GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0840SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-0840IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1303GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1312GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1312SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1312IGSSGYQVISTPTDF823
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1313GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1313SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1330GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1330SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1349GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1390GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1395GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1410GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1410SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1413GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1413SSGYQVISTPTDFFM1025
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1469GSSGYQVISTPTDFF924
BCAS3-PRKAA2chr1758885437chr157157067507DRB1-1469SSGYQVISTPTDFFM1025

Top

Fusion breakpoint peptide structures of BCAS3-PRKAA2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BCAS3-PRKAA2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of BCAS3-PRKAA2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
BCAS3-PRKAA2chr1758885437chr1571570671025SSGYQVISTPTDFFMATCTTCTGGATACCAGGTGATCAGCACTCCAACAGATTTTTTTAT
BCAS3-PRKAA2chr1758885437chr1571570671126SGYQVISTPTDFFMVTTCTGGATACCAGGTGATCAGCACTCCAACAGATTTTTTTATGGT
BCAS3-PRKAA2chr1758885437chr157157067722SIGSSGYQVISTPTDGAGCATTGGATCTTCTGGATACCAGGTGATCAGCACTCCAACAGA
BCAS3-PRKAA2chr1758885437chr157157067823IGSSGYQVISTPTDFCATTGGATCTTCTGGATACCAGGTGATCAGCACTCCAACAGATTT
BCAS3-PRKAA2chr1758885437chr157157067924GSSGYQVISTPTDFFTGGATCTTCTGGATACCAGGTGATCAGCACTCCAACAGATTTTTT

Top

Information of the samples that have these potential fusion neoantigens of BCAS3-PRKAA2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for BCAS3-PRKAA2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BCAS3-PRKAA2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BCAS3-PRKAA2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource